InvestSMART

AdAlta Limited (ASX:1AD)

ALERT: Price-sensitive ASX Announcement for 1AD
Current share price for 1AD : $0.004 0 (0%)+
Announcement
Release
25 May 2026 8:44AM
Price at Release
$0.004
Full Release
download
Summary
AdAlta Limited has issued a Prospectus related to the offering of quoted options (ASX:1ADO) as part of a placement of new shares to raise up to $2.5 million. The Offer is intended for sophisticated and professional investors who participated in the Placement. The company plans to use the funds to advance the development of its armoured CAR-T cell therapy, BZDS1901, and for general working capital. The total number of shares issued will increase by approximately 7.8% if all options are exercised. The issuance of new options is subject to shareholder approval at an extraordinary general meeting on June 15, 2026. AdAlta is leveraging its 'East to West' strategy to bring Asian cellular immunotherapies to Western markets, with a focus on solid cancers and fibrotic diseases.
Key Points
  • AdAlta Limited issues Prospectus for offering of options under Placement.
  • Offer targets sophisticated and professional investors.
  • Placement aims to raise $2.5 million.
  • Funds to advance BZDS1901 therapy development.
  • New options issuance contingent on shareholder approval.
  • Shareholder meeting scheduled for 15 June 2026.
  • Potential 7.8% increase in share capital if options exercised.
  • Strategic focus on cellular immunotherapies for solid cancers.
  • Integration of Asian T cell therapies with Western markets.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.